Psilocybin Shows Promise for Alcohol Use Disorder, but Larger Trials Are Still Needed
Early clinical research suggests that psilocybin-assisted therapy may help some people reduce harmful drinking, but the evidence remains preliminary. A 2025 open-label study involving 10 adults with severe alcohol use disorder (AUD) found that one 25-milligram dose, administered alongside preparation and integration sessions, was followed by lower alcohol consumption, fewer heavy-drinking days, reduced cravings, and greater confidence in participants’ ability to abstain.
The study, published in the Journal of Psychopharmacology, included eight men and two women seeking treatment for severe AUD. Participants completed two preparation sessions, a supervised psilocybin session, and two follow-up integration sessions. Alcohol use was tracked for 12 weeks after dosing.
By the end of the follow-up period, heavy-drinking days had fallen by an average of 37.5 percentage points, while participants reported drinking about 3.4 fewer drinks per day than at baseline. Craving decreased quickly and remained lower during follow-up, and abstinence self-efficacy—the belief that one can avoid drinking—also improved.
These results are encouraging, but the study cannot establish that psilocybin caused the changes. It had no placebo or control group, and participants knew they were receiving psilocybin. Expectations, the structured therapeutic environment, preparation and integration sessions, and participants’ motivation to change could all have contributed to the outcome. The sample was also very small and predominantly male.
The researchers included Nora Volkow, director of the National Institute on Drug Abuse, among the authors. Their conclusion was appropriately cautious: larger randomized, placebo-controlled studies are needed to determine how effective a single dose is and which patients are most likely to benefit.
How the findings fit with earlier research
The 2025 study builds on a longer history of psychedelic research in addiction treatment. A review of classic hallucinogens in addiction treatment examined historical and modern research involving substances such as LSD and psilocybin. The authors described early findings as promising but emphasized that controlled trials were necessary before drawing firm conclusions.
One possible explanation for the lasting effects of psychedelic-assisted therapy is its influence on psychological and neural flexibility. Researchers have proposed that serotonergic psychedelics may temporarily alter patterns of brain activity and promote forms of neuroplasticity—the brain’s ability to adapt and reorganize. These changes could make it easier for some people to reconsider entrenched habits, respond differently to alcohol-related cues, or engage more effectively with psychotherapy.
Neuroplasticity, however, remains a proposed mechanism rather than a proven explanation for improvements in AUD. Positive subjective experiences, therapeutic expectations, the quality of the treatment setting, and the psychological work surrounding the dosing session may be equally important. Researchers are still working to determine whether the intensity of a so-called mystical-type experience predicts clinical benefit or simply reflects other factors associated with treatment response.
Randomized evidence is more informative
Subsequent controlled research provides a stronger test of psilocybin’s potential. In a 2022 randomized clinical trial, 95 adults with alcohol dependence received either psilocybin or diphenhydramine during two medication sessions, together with 12 weeks of psychotherapy. The psilocybin group experienced fewer heavy-drinking days over the study period than the comparison group.
That trial was larger and better controlled than the 10-person open-label study, but it still evaluated psilocybin as part of a broader package of psychotherapy and clinical support. The findings therefore do not show that psilocybin works as a stand-alone medication. They suggest that psychedelic-assisted therapy may become a useful addition to comprehensive treatment for some people with AUD.
Results have not been uniformly positive. A later randomized trial examining a single psilocybin dose after alcohol withdrawal did not find a significant advantage over placebo for relapse prevention. Differences in treatment setting, psychotherapy, participant characteristics, dosing schedules, and outcome measures may help explain why results vary.
An investigational treatment—not a replacement for care
Psilocybin is not a substitute for established treatment or medically supervised alcohol withdrawal. The National Institute on Alcohol Abuse and Alcoholism advises that evidence-based care for AUD can include behavioral therapies, mutual-support groups, and FDA-approved medications such as naltrexone, acamprosate, and disulfiram. People with severe AUD may require medical assistance when stopping alcohol because withdrawal can be dangerous or life-threatening.
Psychedelic treatment also carries risks and requires careful screening and supervision. Clinical studies use controlled doses, trained professionals, preparation, monitoring, and follow-up support. The findings do not justify attempting to self-treat addiction with psilocybin or LSD.
The most useful takeaway from the research is not that psychedelics have already transformed addiction care. Rather, carefully supervised psychedelic-assisted therapy has produced enough promising signals to warrant more rigorous investigation. Future studies will need larger and more diverse samples, credible control conditions, longer follow-up, and clearer evidence about safety, durability, therapeutic mechanisms, and which people are most likely to benefit.
For now, psilocybin remains an experimental approach within the broader treatment landscape for alcohol use disorder. Its potential may ultimately depend not only on the drug itself, but also on the psychological support, clinical setting, and continuing care that surround it.
